At taper week 1 , mean DESS scores were significantly lower for desvenlafaxine 50 mg every other day ( 2.26 , p < 0.001 ) , 50/25 mg/d ( 2.28 , p < 0.001 ) , and 50 mg/d-placebo ( 1.84 , p < 0.001 ) taper regimens vs. no taper ( 7.07 ) .
